Guidelines Endoscopy in patients on antiplatelet or Gut: first published as 10.1136/gutjnl-2015-311110 on 12 February 2016. Downloaded from anticoagulant therapy, including direct oral anticoagulants: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guidelines Andrew M Veitch,1 Geoffroy Vanbiervliet,2 Anthony H Gershlick,3 Christian Boustiere,4 Trevor P Baglin,5 Lesley-Ann Smith,6 Franco Radaelli,7 Evelyn Knight,8 Ian M Gralnek,9,10 Cesare Hassan,11 Jean-Marc Dumonceau12 For numbered affiliations see ABSTRACT guidelines on the management of acute non- end of article. The risk of endoscopy in patients on antithrombotics variceal upper gastrointestinal bleeding.1 Correspondence to depends on the risks of procedural haemorrhage versus Recommendations for the management of Dr Andrew Veitch, Department thrombosis due to discontinuation of therapy. patients on antiplatelet therapy or anticoagulants of Gastroenterology, New P2Y12 receptor antagonists (clopidogrel, undergoing elective endoscopic procedures are out- Cross Hospital, Wolverhampton prasugrel, ticagrelor) For low-risk endoscopic lined in the algorithms in figures 1 and 2. Risk WV10 0QP, UK; procedures we recommend continuing P2Y12 receptor stratification for endoscopic procedures and anti-
[email protected] antagonists as single or dual antiplatelet therapy (low platelet agents (APAs) are detailed in tables 1 and This article is published quality evidence, strong recommendation); For high-risk 2. There is no high-risk category of thrombosis for simultaneously in the journal endoscopic procedures in patients at low thrombotic risk, DOACs as they are not indicated for prosthetic Endoscopy. Copyright 2016 © we recommend discontinuing P2Y12 receptor metal heart valves. Warfarin risk stratification is Georg Thieme Verlag KG antagonists five days before the procedure (moderate detailed in table 3.